Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1 Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 5190457 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms SAD
  • Sponsors Pfizer

Most Recent Events

  • 05 Nov 2020 Results (n=47)of pooled analysis from NCT01247896 and NCT02039349 evaluaitng population pharmacokinetic model for PF-5190457, published in the Clinical Pharmacokinetics
  • 13 Sep 2016 Results assessing safety, pharmacokinetics and pharmacodynamics of SAD and MAD studies published in the British Journal of Clinical Pharmacology.
  • 05 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top